Sabine D. Brookman-May
@brookmans76
Followers
2,719
Following
2,258
Media
286
Statuses
1,126
Professor of Urology @LMU_Muenchen , Vice President R&D Bladder Cancer, @JNJInnovMed , GU Oncology, Sports Medicine 🚵♀️Passionate Cyclist
Pennsylvania, USA
Joined February 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Olympics
• 3648433 Tweets
Venezuela
• 1163798 Tweets
Jesus
• 786057 Tweets
Christianity
• 513987 Tweets
Bitcoin
• 511084 Tweets
Last Supper
• 381608 Tweets
Hezbollah
• 376126 Tweets
Chelsea
• 160380 Tweets
The Villages
• 138782 Tweets
Sanchez
• 115771 Tweets
Druze
• 107447 Tweets
لبنان
• 97363 Tweets
Lebanon
• 91668 Tweets
C Spire
• 69251 Tweets
Yankees
• 60871 Tweets
Demichelis
• 55824 Tweets
Jazz
• 55572 Tweets
#アイドルへモーニングコール
• 47003 Tweets
Gallardo
• 44743 Tweets
Maresca
• 33094 Tweets
Gary Gensler
• 32985 Tweets
Apollo
• 29968 Tweets
#UFC304
• 29412 Tweets
Babi
• 19651 Tweets
Giannis
• 19005 Tweets
Rony
• 17344 Tweets
#ボクらの時代
• 16666 Tweets
Shai
• 16314 Tweets
Dionysus
• 14697 Tweets
ブライアン
• 11804 Tweets
Paiva
• 10217 Tweets
#JoyceChisora
• 10198 Tweets
STOPCAP meta-analysis:
Docetaxel addition to ADT
➡️ limited OS/PFS benefit in low-volume metachronous mCSPC
➡️ best suited for high volume/potentially bulky/T4 primary tumors
@ChrisSweens1
@BertrandTOMBAL
@pgd81
@mattsydes
@Prof_Nick_James
#ProstateCancer
1
76
155
Happy to start my role as Vice President
#BladderCancer
Development Head at
@JanssenGlobal
R&D today. After academic work on
#KidneyCancer
, several years in
#ProstateCancer
research + parallel to ongoing patient counseling, it is a great move for a urologist
#ILookLikeAUrologist
24
7
108
PSA >0.25 at time of post RP salvage therapy significantly increases all cause mortality in
#ProstateCancer
pts. Another call for early salvage treatment. Would be great to see data on PC-related death and competing risks
@Tilki_De
@felixfengmd
#D
’Amico
9
26
104
Great news today 👉Breakthrough Therapy Designation for TAR200🥨based on results of SunRISe-1 for potential future treatment of patients with BCG unresponsive HR-
#NMIBC
, ineligible for RC/decided not to undergo RC
#BladderCancer
#MyCompany
@JNJInnovMed
👉
6
38
104
Matched comparison of
#TrimodalTherapy
/TMT vs
#RadicalCystectomy
for
#MIBC
:
➡️No sign. differences in cancer-specific + disease-free survival
➡️Overall survival favoured TMT
➡️Salvage cystectomy needed in 13% + 20% with MIBC recurrence
👉Every bladder spared counts!
@urotoday
Radical Cystectomy vs. Trimodality Therapy for Muscle-Invasive
#BladderCancer
. A multi-institutional analysis unveils surprising results. Bladder preservation is a compelling alternative! 📚 Read the study insights here >
#BladderHealth
@TheLancetOncol
0
11
23
0
43
94
Finally published - thanks to the leadership of
@amerseburger
@neerajaiims
@bjartell
: subgroup analysis of
#TITAN
analysis:
➡️
#Apalutamide
+ADT improved outcomes in
#mCSPC
regardless of disease burden
➡️ highest benefit in oligometastatic bone-only disease
Out now: Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
@neerajaiims
@scserendipity1
@brookmans76
@bjartell
3
27
81
3
26
77
#EMBARK
results presented by
@nealshore
at
#AUA2023
MFS significantly improved with enza/ADT vs ADT in HR
#BCR
; HR 0.42. Striking that also enza mono improved MFS vs ADT: would be interested to see whether NHT mono reduces the risk of competing risks of death as one explanation?
4
24
67
Very happy to share our Platinum Opinion on intermediate and clinically meaningful
#endpoints
reflecting patient benefit in localized
#ProstateCancer
👉A roadmap for future endpoint development
👉
@EUplatinum
@ChrisSweens1
@SFreedlandMD
@felixfengmd
3
21
61
Patients with very high-risk
#NMIBC
receiving adequate
#BCG
therapy show better outcomes than predicted by EAU risk classification in this retrospective multi center cohort
👉
@EUplatinum
@urotoday
@JGomezRivas
@BenjaminPradere
@LAUrology_NL
@EAUYAUrology
1
18
56
ERSPC Update on
#ProstateCancer
#screening
after a median 21 yrs follow-up:
➡️Metastasis + mortality reduction continue to increase
➡️Reduced prostate cancer specific mortality: RR of 0.73 (95%CI: 0.61–0.88)
➡️More favorable harm-benefit ratio over time
3
26
52
#ESMO23
Late Breaker
#SunRISe1
#TAR200
🥨 in patients with BCG unresponsive HR
#NMIBC
:
➡️ 77% CR (23/30 pts)
➡️ Durable response at 6 months post CR in 11/11 pts
➡️ Durable response at 12 months post CR in 6/6 pts
@JanssenGlobal
@AndreaNecchi
@evanguelosx
@Lash7587
@siadaneshmand
2
25
54
Please retweet and spread: In parallel to the 2nd ed. Roulons Contre Le Cancer
#ProstateCancer
Charity Event,
@BenjaminPradere
and I will be organizing a
#Roadbike
Friendship Group Ride🚴♀️🚴🚴♂️in Chicago during
#ASCO2023
. Date: June 3rd, 8 am CT, meeting point tbd, 2-3-4 hours
3
31
52
Comprehensive overview: Urinary tract
#microbiome
+
#BladderCancer
🔵Interaction of microbiome - metabolites - immune response➡️Inflammation vs antitumor
#immunity
➡️Cancer development/progression➡️Impact on biological behavior of tumors
🔵Potential therapeutic applications👇
3
8
50
Excellent assessment of the role of
#LND
in
#ProstateCancer
#KidneyCancer
#UTUC
#BladderCancer
:
🔵LND = best staging method
🔵Accuracy depends on LND template
🔵Individual Risk-Benefit assessment of staging/therapeutic benefits + pt selection is key
👉
Our collaborative review on LND in GU cancers; tremendous effort by
@AmandaMyersMD
@MDAndersonNews
#OncSurgery
@EurUrolOncol
Open Access link:
@Albert0Briganti
@BradLeibovichMD
#SethLerner
@UroMoschini
@MRoupret
@DrShariat
@SpiessPhilippe
@Astenzl
5
99
245
0
17
51
Full FDA approval for
#Erdafitinib
for the treatment of pts with locally advanced/metastatic FGFR+
#UrothelialCarcinoma
following prior systemic therapy, based on data from THOR/Cohort 1): 36% risk reduction in death in pts with prior PD1/PDL1 inhibition vs chemo
@JNJInnovMed
1
15
47
#ESMO23
First results of
#TAR210
🥨 in patients with
#NMIBC
👉 Promising efficacy data:
➡️ High recurrence free/complete response rate: 82% and 87%
➡️ 11/13 evaluable patients (BCG exp. HR
#NMIBC
) + 13/15 (IR
#NMIBC
) recurrence free
#AntoniVilaseca
@JanssenGlobal
1
22
48
Great presentation of
#ARNEO
results by
@joniau
#UroOnco23
Neoadjuvant treatment apa/ADT vs ADT prior to RP in
#prostatecancer
: BCR not sign. different yet + MRD does not seem to be a good surrogate for BCR. But: downstaging to pT2 was higher with apa/ADT + correlated with BCR
1
10
47
Great to see my
#vineyard
in a good shape
#Shiraz
#Monastrell
🍇🍷 And just ordered white wine to start planting on the next lot in March
#Viognier
#Parellada
#Mallorca
10
0
45
SunRISE-1 results reported at
#AUA2023
for TAR200 mono (local gemcitabine🥨delivery system) + Cetrelimab mono in BCG-refractory high-risk
#NMIBC
➡️72.6% complete response with TAR200 mono + well tolerated
@siadaneshmand
@kakeegs3
@Sweiti
GiuseppeSimone, MichielVanderHeijden
3
8
45
Outcomes of 61,777/62,361 US pts with localized
#ProstateCancer
(claims/electronic health records):
✅Mostly RP (EHR) or RT (claims) as primary treatment
✅Better OS in men treated with RP
✅No Evidence of Disease (NED) at 4 yrs sign. correlated with OS (age/comorbidity adjusted)
4
19
42
Excellent review/MA: non-surgical interventions 5ARI, ARSI, exercise in
#ProstateCancer
#ActiveSurveillance
👉Risk of bias↗️ no reliable conclusions (yet)
👉Adding some more concerns: biopsy detection bias ➡️impact on PFS, next treatment subjectivity, possible rebound (ENACT)👇
1
14
42
Excellent mini review
@DrShariat
@E_Laukhtina
Next goal in
#BladderCancer
👉Bladder Preservation
Tasks to work on:
✅Reliable
#biomarker
/clinical/AI models to predict pT0 ➡️cT0 is not enough
✅Surveillance protocols
✅Adaptive study designs: induction treatment w/wo Cx
@EUplatinum
For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy - European Urology Focus
1
12
40
1
15
40
Congratulations to
@MRoupret
@AStenzl
@uroweb
for delivering this newborn
#UroOnco23
A great first event:
👉 Great speakers
👉 Excellent GU oncology coverage: new data presentation, state of the art lectures, clinical case discussions, workshops
Looking forward to
#UroOnco24
!
1
9
42
Updated data from Sunrise1
#TAR200
study presented by
@JoeJacobMD1
in patients with CIS +/-papillary HR
#NMIBC
#AUA24
✅ 82.8% Complete Response (CR) rate per central review/86.2% per local assessment
✅ 98% of CRs were achieved within 12 weeks
@JNJInnovation
#MyCompany
#MyTeam
1
12
41
How can ctDNA be implemented for
#ProstateCancer
in the clinic? Great presentation by
@ResearchWyatt
➡️ Value of ctDNA as prognostic indicator with higher diversity than single metastasis/better snapshot of the tumor profile + possible treatment response
#biomarker
0
12
40
#ESMO23
@JimCatto
THOR-2 cohort 1 results of
#erdafitinib
vs intravesical chemo in HR
#NMIBC
+
#FGFR
alterations after prior BCG:
➡️RFS reduced by 72%
➡️Due to systemic erda side effects,
#TAR210
being developed for local delivery 👉 more to be presented at
#ESMO23
@JanssenGlobal
1
17
40
Happy to share convincing results from our recent MA: outcomes of RARP/LND + peritoneal interposition flap (PIF)
#ProstateCancer
👉 OR 0.46/0.51 for symptomatic/overall lymphocele, 0.41 for grade ≥3 complications
👉 no functional impairment
@EurUrolFocus
3
7
37
#ESMO23
#ABACUS
Trial: Neoadjuvant atezolizumab in non-urothelial
#BladderCancer
subtypes
@b_szabados
👉 Striking discrepancy btw local vs central pathology
❓Pathologists
@Markuseckstein3
- why is that? For nonUC subtypes, but also for UC grading. Can consistency be improved?
8
10
38
Additional evidence that
#ctDNA
status prior to
#RadicalCystectomy
is a prognostic marker for nodal involvement and metastatic disease
Peter Wiklund presented data from 117 MIBC patients
@ReubenBenDavid1
#EAU24
#BladderCancer
#Biomarker
0
10
38
#Movember
has started! Raising awareness and money for
#MensHealth
#ProstateCancer
#TesticularCancer
Would love to grow a Mo, but since I cannot, will fundraise through
#Cycling
, rowing, hiking, skiing. Welcome everybody who wants to join my team (right now n=1) 🚴🚴🚴🚣⛷️🏃
1
3
36
Residual high-risk
#UTUC
after
#NAC
carries a poor prognosis:
➡️Poorer RFS (HR 3.07, 95%CI 2.10–4.48), OS (HR 2.06), CSS (HR 2.54) compared to risk-matched pts w/o NAC
➡️We need appropriate adjuvant treatment strategies
👉
@EurUrolOncol
@SeanFletcherMD
Thanks to
@EurUrolOncol
for publishing our work on characterizing oncologic outcomes among patients with residual
#UTUC
following NAC and RNU in a multicenter, international cohort
3
11
77
1
14
35
What a great ride 🚴today in Chicago
#ASCO2023
! Paralleling same date as Mount Ventoux ride France - Friendship
#Roadcycling
- including some climb + steps. Next year mount Ventoux@
@BenjaminPradere
@VerhoestGregory
please share more pics! Finally finishing with a great beer🍻
2
5
36
Prostate Subtyping Classifier/PSC developed on >100,000 samples using machine learning for
#ProstateCancer
expression signatures:
1️⃣ luminal differentiated/LD
2️⃣ luminal proliferating/LP
3️⃣ basal immune/BI
4️⃣ basal neuroendocrine/BN
@JournalCancer
👇
1
12
34
4
0
35
#PSMAfore
phase 3 trial of
#LuPSMA617
in taxane-naive
#mCRPC
patients
@sartor_oliver
#ESMO23
☢️ PFS signifcantly improved
☢️ OS no significant difference with 84% crossover
👉
@ChrisSweens1
discussed results ➡️ Use the Sweeney Clinical Benefit Rating for clinical intelligence
2
13
35
Great talk by
@GPloussard
Combination of systematic and targeted
#biopsy
should still be the gold standard to detect clinically significant
#ProstateCancer
and allow better prognostic and treatment counseling also due to lower rates of Gleason Score upgrading from biopsy to RP
0
8
34
Having a break from
#Cycling
today in
#Mallorca
releases some time to visit my
#Vineyards
and the
#Winery
#VinoDeLaIsla
1
0
34
EV-302 results finally in
@NEJM
-
#Enfortumab
#Pembro
in metastatic
#Urothelial
#Cancer
Beyond the questions asked by
@Markuseckstein3
, interested to see activity in other disease settings, such as neoadjuvant prior to RC
@tompowles1
@shilpaonc
@urotoday
👉
🚨🚨 EV-302 data finally published
@NEJM
! Such a breakthrough for
#metastatic
#urothelial
#cancer
with doubling in OS and „insane ORR“.
👉 First
#therapy
improving OS massively by doubling overall survival of frontline metastatic patients‼️
👉 All subgroups show huge benefits‼️
0
19
54
0
9
33
Ready to be used in clinical trials + in clinical setting:
#RECIP
1.0 response evaluation criteria for
#PSMA
PET/CT
#ProstateCancer
👉 We should start getting
@RECIP_criteria
consistently implemented to generate consistent evidence with this framework
👉
RECIP 1.0 criteria determined by visual reads of nuclear medicine specialists showed 95% accuracy and excellent inter-reader agreement.
@radiology_rsna
Visual RECIP 1.0 is ready for use in daily practice and clinical trials for PCa therapy monitoring.
0
2
7
0
7
33
Antoni Vilaseca presenting updated data on
#TAR210
FIH study in patients with
#FGFR
+
#NMIBC
today at
#AUA24
✅90% estimated 12 months RFS in BCG experienced HR NMIBC
✅90% CR in IR NMIBC
#BladderCancer
@JNJInnovation
#MyCompany
#Erdafitinib
0
17
33
EMBARK study exploring enzalutamide+ADT vs ADT/placebo vs enza mono in nmCS
#ProstateCancer
and high-risk BCR met the primary endpoint MFS. Sign. difference also between Enza mono vs ADT/. Curious to see OS, subsequent treatment, PRO data
@SFreedlandMD
@nealshore
@marty_gleave
0
11
31
Looking forward to presenting current
#BladderCancer
#Research
and exchanging on future directions for research at
#EAU24
new initiative Flash Presentations together with
@DrFelixGuerrero
and
#JuergenGschwend
@JNJInnovMed
@Uroweb
1
7
31
Sharing our study on disease trajectory among men with HR localized
#ProstateCancer
treated with RP or RT from the PC database Sweden
▶️10% of men overall died from PC in 10 years post diagnosis
▶️1/3 of men who received secondary ADT died from PC 10 years after ADT
@BJUIjournal
0
8
31
#BladderCancer
#NMIBC
molecular profiling uncovered 3
#BCG
response subtypes
👉BRS3: 1⃣reduced RFS + PFS 2⃣high EMT 3⃣basal markers⬆️ 4⃣immunosuppressive profile
👉Molecular subtypes outperformed risk stratification by clinicopathological variables
@Dan_Theodorescu
@TDLaajala
0
14
31
Excellent talk about treatment intensification in men with metastatic hormone-sensitive
#ProstateCancer
by
@ChrisSweens1
incl. the use of living network meta-analysis for cross trial comparison to generate more evidence from existing studies and datasets
#ENZAMET
#ARASENS
0
6
31
#BladderCancer
awareness must be improved. Confirmed again:
▶️
#Awareness
is poor + associated risk often unknown
▶️Diagnostic delay/misdiagnosis frequent in♀️
▶️
#SexualFunction
counselling prior to RC is often not performed
@UroDocAsh
@lydiamakaroff
@pcvblack
@WorldBladderCan
👏 An inspiring session at
#SIU2023Istanbul
with our President
@lydiamakaroff
presenting WBCPC survey findings poster.
❗The poster showcases key elements of
#bladdercancer
experience with care & the importance of awareness raising and peer support.
Check out the poster👉
1
6
14
1
10
30
Again evidence that high
#coffee
intake might improve outcomes in men with
#ProstateCancer
👉 Longer CSS in men with
1️⃣ localized disease (HR 0.66, 95% CI 0.44–0.98; p = 0.040)
2️⃣ CYP1A2 AA genotype (HR 0.67, 95% CI 0.49–0.93; p = 0.017)
@JustinRGregg
@carrie_d_mac
@EurUrolOncol
1
10
30
Fantastic! After coming back home from
@uroweb
#EAUTalentIncubator
@eau_yuo
my Christmas present has finally arrived - my Berkel BS300
#BerkelWorld
A dream comes true!
2
0
29
#ASCO2023
abstract
#5010
: W. Fendler,
@ProfHadaschik
@ProfKHerrmann
@CalaisJeremie
@DrMHofman
@CzerninJohannes
et al. evaluating the prognostic value of PSMA-PET disease extent in nm (by CT/MRI) CRPC for OS/newMFS. >5 mets on PET + initial pN1 significantly associated with OS
3
7
28
SURE-01: neoadj SG +/- pembro in
#MIBC
#ASCO24
✅ 36% pCR/45% ypT≤1N0 (RC) + 6/7 pts refusing RC with clinical CR (MRI/cysto/ctDNA/TURBT-)
👉 potential
#BladderSparing
approach?
🔹Proper AE management required
#GCSF
@oncodaily
@urotoday
@AndreaNecchi
@Anto_cigliola
@ASCO
3
13
28
#ESMO23
Late breaker: FIH Study
#TAR210
intravesical
#Erdafitinib
delivery system for
#FGFR
+
#UrothelialCarcinoma
:
👉High recurrence free/complete response rate
👉11/13 evaluable patients (BCG exp. HR
#NMIBC
) + 13/15 (IR
#NMIBC
) recurrence free
#AntoniVilaseca
@JanssenGlobal
2
14
27
Interesting debate on primary RT+ADT vs ADT+ARTA with
@AttardLab
, Nicolas Mottet in
#ProstateCancer
pts low volume on conventional imaging + up to 5 PSMA-PET lesions: No level 1 evidence available to answer this question. Can Stampede results help make pragmatic decisions?
#EAU23
2
4
28
Enjoyed being a speaker at day 1 of
@Uroweb
#EAUTalentIncubator
in Innsbruck. Great group of motivated young urologists participating!
#LeasershipInUrology
@JLVasquez82
0
5
26
@tompowles1
@MattGalsky
@NatureMedicine
Definitely time to move into a
#cystectomy
free era. The time has come for bladder-sparing approaches. Urology is obviously moving in this direction. Lots of tasks remain to safely avoid cystectomy, but we will find the right
#biomarkers
to accomplish this goal
#BladderCancer
1
5
27
DFS is important in the adjuvant setting and it is great to finally see OS benefit in
#KN564
after adjuvant
#RCC
treatment, BUT:
➡️With OS not being the primary EP, informative
#censoring
+ unequal subsequent
#treatment
may impact results
👉
@TomerMeirson
@DrChoueiri
@BusinessWire
@DanaFarber_GU
@tompowles1
@OncoAlert
@OncBrothers
@OncLive
@TargetedOnc
@urotoday
@Uromigos
@ALLIANCE_org
@eaonc
@SWOG
@ASCO
@NEJM
@myESMO
@AmerUrological
@montypal
@neerajaiims
@mtmdphd
@KidneyCancer
@kidneycan
one of the knocks against KN 564 is cleared with the OS benefit - suspect that the trial won out from imbalance in informed censoring ( while all the other IO adj trials failed )
0
1
6
1
6
27
How can we qualify men with GG2
#ProstateCancer
for
#ActiveSurveillance
? Great talk by
@dr_coops
at
#EAU23
outlining options to improve patient selection with clinical characteristics/CAPRA-Score -/+ additional genomic risk-classifiers (Decipher, Artera, Prolaris, Oncotype)
0
9
27
Excellent discussion of
#EV302
and
#CM901
studies and results + bringing all past/negative/ongoing studies with ICI in first line mUC into context
@apolo_andrea
#ESMO23
👉 Hopefully more to come for EV/Pembro combo in other
#BladderCancer
disease stages ➡️
1
6
27
@TylerSbrt
@VedangMurthy
@AdamSharpMedOnc
@cwspeers
@aadel_chaudhuri
@_ShankarSiva
@andreasroder1
@shiv_smith
@ethansgrumps
@RenuEapen
@SbrtSean
@cancerphysicist
@ProfAJChalmers
@paulpharoah
@PercyLeeMD
Last week at this time on the
#Roadbike
#Mallorca
Cap Formentor
3
2
26
Full publication Phase 3 Titan Study results on low/volume subgroups in mCSPC
#ProstateCancer
👉
Great work together with
@amerseburger
@bjartell
@neerajaiims
@scserendipity1
@MundleSuneel
1
11
26
Finally - European commission added
#ProstateCancer
to recommended
#Screening
programs. Next step: make sure we get true risk based screening well done and reduce mortality, but also over diagnosis and over treatment by proper use of risk-calculators, MRI, possibly even PSMA-PET.
1
8
25
To do or not to do - Re-
#TURBT
? Supporting arguments on both sides
@jteoh_hk
and
@bkonety
“Do it right the first time” (Jeremy Teoh) or despite that still needed?
#BladderCancer
0
5
24
As for
#ProstateCancer
, should future
#KidneyCancer
trials stratify for disease burden to identify pts with best risk/benefit from
#triplet
regimen? Valuable LttE addressing COSMIC-313 outcomes
@carme_mir1
@BenjaminPradere
@CerratoMd
@AlbigesL
@tompowles1
@DrChoueiri
@EUplatinum
2
9
24
@DrFelixGuerrero
@josedsh
@RodriguezFaba
@dr_romero_otero
@fcounago
@BladderCaJrnl
Excellent review, thanks for referencing. Looks like prediction models (EORTC, CUETO, EAU 2021) + expert opinion (AUA, prior EAU, 2020, NCCN) poorly discriminate NMIBC recurrence risk, slightly better progression👉novel models with clinicopathological/molecular factors needed
1
11
22
To my X community: I am searching for a Medical Director/Senior Medical Director in my R&D team at Johnson and Johnson for
#BladderCancer
. Link for application: Also reach out to me directly with any questions
1
3
23
This was a tough one! Rhön300
#Roadbike
Marathon - 231 km - 4530 altimeters 🚴♀️🚴🚴🚴⛰️⛰️⛰️ But great as always to start a ride in my original home village
2
0
23
Applications open for
@Uroweb
#TalentIncubator
in Innsbruck/Austria Jan 2024 for young urologists up to 45 yrs. Very happy to be one of the speakers ➡️Develop skills beyond medicine + become a versatile
#EmpoweredUrologist
#ILookLikeAUrologist
@JLVasquez82
2
5
23
How does 18F-rh
#PSMA
-7.3 perform in UIR/HR/VHR
#ProstateCancer
patients for detection of pelvic lymph nodes, validated by pathology?
#LIGHTHOUSE
1️⃣ High specificity in all groups 93-97%
2️⃣ Sensitivity goal not met 23-30%
3️⃣ Patient-level sensitivity ⬆️ in HR/VHR up to 53%👇
1
7
22
Great review on smoking, RR⬆️, lifestyle impact on
#KidneyCancer
incidence/outcomes. Proper conclusions, but I think we need to get rid of the obesity paradox👉likely a result of poor study designs and missing adjustment for earlier diagnosis, weight loss, other confounders
2
6
23
Comprehensive summary by
@wandering_gu
of updated
@AmerUrological
AUA guidelines on decision making at
#BCR
after RP
#ProstateCancer
highlighting the need to consider risk factors and the role of
#PSMAPET
#AUA24
#SalvageRT
1
5
23
A really great session at
#AUA24
Thank you
#IBCG
@UroDocAsh
for an excellent agenda, great debates and speakers
#BladderCancer
Beyond others
@AStenzl
@PGrivasMDPhD
debating the need of RC in cT0 after NAC/NIO
👉biomarkers/ctDNA/MRI may help to select pts, but more evidence needed
0
5
24
Finally out: results of the legacy phase 1b study which built the groundwork for our ongoing phase 2 + 3 studies with the intravesical gemcitabine releasing system TAR-200 🥨
➡️TAR-200 was safe + well tolerated, with encouraging preliminary efficacy in IR
#NMIBC
@JNJInnovMed
3
5
22
Meta-Analysis on First-line Systemic Treatment Options for patients with metastatic hormone-sensitive
#ProstateCancer
just published in
@JAMAOnc
Great work done by
@AlanBryce9
et al.
1
10
22
Happy to share results from
#TITAN
(Apalutamide+ADT vs Pbo+ADT, mCSPC) with
@scserendipity1
@bjartell
, Kim Chi as lead authors: PSA decline ≥90% or to ≤0.2 ng/ml at 3 months is associated with significantly longer OS (HR 0.35), rPFS (0.44), time to PSA prog/CRPC (0.31/0.38)
1
9
22
Confirmed again that PSA decline and timing of PSA response is a prognostic factor for short and long-term outcomes in
#ProstateCancer
@amerseburger
@neerajaiims
@alvarojuarezs
@MundleSuneel
1
10
22
#Enzamet
primary OS analysis published with 5-year OS of 57% (0·53–0·61) in control vs 67% (0·63–0·70) in enza group incl. analysis of predefined prognostic subgroups (synch/metachron/high/low-volume) + planned use of concurrent docetaxel
@ChrisSweens
@ChrisSweens1
et al; Long-term outcomes data from ENZAMET trial at this link – 50 days free access to full publication
0
5
12
1
8
22
Excellent coverage on lymph-node only metastatic
#UrothelialCancer
as a distinct entity among complete responders to Nivo/GC
#CheckMate901
➡️Med OS in LN-only mUC: 46.3 (Nivo+GC) vs 24.9 months with GC (HR 0.58)
👉
@MattGalsky
@urotoday
@oncodaily
#ASCO24
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic
#UrothelialCarcinoma
from
#CheckMate
901. Presented by
@MattGalsky
.
#ASCO24
written coverage >
0
12
18
2
1
21
#ESMO23
Presidential session
@tompowles1
#Enfortumab
+
#pembrolizumab
vs platinum based chemotherapy
👉 55% + 53% reduction for risk of progression and death
👉 First time since decades, superiority shown over Cisplatin based chemo in mUC
#bladdercancer
@urotoday
@Uromigos
0
4
22
It is a call for action without any doubts
@UroDocAsh
More awareness needed on
#BladderCancer
and preventive measures + dedicated and targeted research. More awareness and research is also required related to the worse
#prognosis
of females compared to males
The surge in
#bladdercancer
diagnoses underscores the pressing need for heightened GLOBAL awareness, research, and preventative measures. A crucial call to action.
@WorldBladderCan
@BladderCancerUS
@IBCG_BladderCA
2
16
37
1
10
22
#ESMO23
Phase 3 Titan trial, ADT+
#Apalutamide
in mCSPC
#ProstateCancer
👉
➡️More pts achieved PSA<=0.02ng/ml with apa compared to ADT only
➡️Deeper decline/Earlier onset of ultra low PSA👉longer survival
@amerseburger
@neerajaiims
@scserendipity1
@urotoday
0
3
22
#Roadbike
fetched from Bobby’s Bike Hike and ready to go for the Friendship
#ProstateCancer
a bike ride tomorrow morning
➡️ Start at 8:30 am at Bobby’s Bike Hike 540 N Lake Shore Dr
➡️ Planned to be back right in time for the GU Poster Discussion Session at
#ASCO2023
1
4
22
#ASCO2023
presented by
@y_loriot
results from THOR 3 showing OS benefit of
#erdafitinib
in pretreated mUC patients with FGFR alterations + discussion by
@DanielPetrylak
➡️
#FGFR
testing should be done, preferably as early as possible
0
6
21
It has been a pleasure to participate in
#EAU
@eau_yuo
#TalentIncubator
1 + 2 and to contribute to this publication
@EUplatinum
I hope this editorial can provide guidance and kick-off some actions to develop the
#urologist
of the
#future
in the best way
Dive into our latest publication with great takeaways from the first modules of the
@eau_yuo
talent incubator
@so_uro
@Uroweb
@EAUYAUrology
@EUplatinum
@JLVasquez82
@brookmans76
@NicholasRaison
@bobkeenan13
@urologybug
1
1
7
0
4
20
Any chance to extend time without
#Castration
in men with
#ProstateCancer
is worth being assessed 👉MA of 22 prospective studies on metastasis directed therapy
#MTD
:
➡️ 2-yr PFS 46%
➡️ 2-yr LC, ADT-FS, OS: 97%, 55%, 97%
➡️ More data needed for OS, ideally from randomized trials
Direct treatment of metastases is a promising option for selected prostate cancer patients. It can delay hormone therapy and is being investigated as a way of intensifying treatment at the expense of manageable toxicity.
0
10
41
1
6
21
After going back to Germany over the summer, just signed up for 2 of the most beautiful
#roadbike
marathons in
#Bavaria
👉
#Rh
ön300 August 5/300km/5300hm+
#ArberRadMarathon
July 30/250km/3750hm - shorter tours available as well 🚴♀️🚴♀️🚴♀️ Hope for some friends on the bike to join!
2
0
21
#UroOnco23
@uroweb
Seth Lerner presenting an overview on new treatments for upper tract
#UrotheliCancer
Already FDA approved
#Jelmyto
for TaLG. What comes next? Light activated endoluminal treatment
#Padeliporfin
and biodegradable drug eluding stents in development. More to come
0
4
21
Very low risk of
#ProstateCancer
death by age of 85 in 70–74 yr old men with prior
#PSA
#screening
➡️PCSM 0.54% in all men, 0.11% (PSA <2) 0.85% (PSA 2–3), 6.8% (PSA ≥6.5)
➡️Screening may be discontinued in men with PSA <3.0
👉
@IvodeVos
@MoniqueRoobol
0
7
21
Tumor fraction and copy number burden using
#utDNA
may be an excellent biomarker for minimal residual disease
#MRD
to be used for surveillance in high-risk
#NMIBC
#BladderCancer
@jlinscott_uro
@UrogerliMD
0
6
21